Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant interferon in the treatment of melanoma.
Middleton MR. Middleton MR. Br J Cancer. 1999 Aug;80(11):1679-80. doi: 10.1038/sj.bjc.6690582. Br J Cancer. 1999. PMID: 10468281 Free PMC article. No abstract available.
Adjuvant interferon in melanoma - a resurrection?
Middleton MR, Thatcher N. Middleton MR, et al. Br J Cancer. 2001 May 4;84(9):1141-2. doi: 10.1054/bjoc.2001.1798. Br J Cancer. 2001. PMID: 11336461 Free PMC article. No abstract available.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G. Gogas H, et al. Ann Oncol. 2006 Dec;17(12):1835-41. doi: 10.1093/annonc/mdl311. Epub 2006 Sep 15. Ann Oncol. 2006. PMID: 16980601 Free article. Clinical Trial.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Kirkwood JM, et al. Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2. Clin Cancer Res. 2012. PMID: 22048237 Free PMC article. Clinical Trial.
New challenges in endpoints for drug development in advanced melanoma.
Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. Ribas A, et al. Among authors: middleton mr. Clin Cancer Res. 2012 Jan 15;18(2):336-41. doi: 10.1158/1078-0432.CCR-11-2323. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142824 Free PMC article.
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, Testori A, Bédane C, Konto C, Dueymes A, Sbarigia U, van Baardewijk M. Johnston K, et al. Eur J Cancer. 2012 Sep;48(14):2175-82. doi: 10.1016/j.ejca.2012.03.003. Epub 2012 Apr 3. Eur J Cancer. 2012. PMID: 22480965
234 results